Conduct of Collaboration Sample Clauses

Conduct of Collaboration. During the Research Term, the parties shall use commercially reasonable efforts to conduct the Research Program in accordance with the Research Plan and the terms of this Agreement. The initial Research Plan for conducting the Research Program will be completed and approved by the JRC within thirty (30) days of the Effective Date. Any amendments or revisions to the Research Plan shall be in writing and shall require unanimous approval of the JRC. Pursuant to the Research Program, the parties will collaborate in identifying and testing Collaboration Target/Chemistries for development and commercialization.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Conduct of Collaboration. 5 3.1 General.........................................................5
Sample 1Sample 2
Conduct of Collaboration. 2.2.1 MERCK shall be responsible for all formulation, preclinical development, clinical development and regulatory work, and manufacturing of clinical supplies pursuant to the Drug Development Plan. Merck shall use Commercially Reasonable Efforts to perform the Drug Development Plan. MERCK shall be responsible for all regulatory activities, both prior to and after obtaining Marketing Authorization, including global safety reporting. MERCK shall be entitled to utilize the services of Third Parties to perform its Collaboration activities. To the extent MERCK determines to use DOV as a Contract Research Organization ("CRO"), such activities shall be pursuant to an agreement containing customary terms and conditions and commercial terms negotiated in good faith between the Parties. Pursuant to such an agreement, DOV shall use only Clinical Trial facilities approved in advance by MERCK, and shall be entitled to utilize the service of Third Parties to perform its activities as a CRO only upon MERCK's prior written consent. Notwithstanding any such consent, each Party shall remain at all times fully liable for its respective responsibilities under the Collaboration. [LOGO] Restricted Confidential Limited Access
Sample 1
Conduct of Collaboration. Each Party shall (a) perform the activities assigned to it under each Collaboration Plan, (b) use Commercially Reasonable Efforts to achieve the objectives allocated to it under each Collaboration Plan, and (c) use Commercially Reasonable Efforts to perform such activities in accordance with the timeline and other requirements set forth therein. Each Party shall conduct such activities in good scientific manner and in compliance with all applicable Laws, including cGMP, GLP and GCP, as applicable.
Sample 1
Conduct of Collaboration. Isis will conduct its work under the Collaboration in a good scientific manner, and in compliance with all applicable good laboratory practices, and all Applicable Laws, to use Commercially Reasonable Efforts to efficiently and expeditiously achieve the Objective of each Collaboration Program.
Sample 1
Conduct of Collaboration. Genetronics and Merck each shall proceed diligently with the work pursuant to the Collaboration by using their respective commercially reasonable good faith efforts to allocate sufficient time, effort, equipment and facilities to the Collaboration and to use personnel with sufficient skills and experience as are reasonably required to accomplish the Collaboration in accordance with the terms of this Agreement. Genetronics and Merck each shall conduct the Collaboration in compliance with all applicable laws, rules and regulations. In addition, if animals are used in research hereunder, Merck encourages Genetronics to use the highest standards, such as those set forth in the Guide for the Care and Use of Laboratory Animals (NRC, 1996), for the humane handling, care and treatment of such research animals. Each Party hereby certifies that it has not, and will not, employ or otherwise used in any capacity the services of any person debarred under United States law, including but not limited to Section 21 USC §335a, in performing any portion of the Collaboration. Either Party shall be entitled to utilize the service of Third Parties to perform its Collaboration activities, but only upon the other Party’s prior written consent. Notwithstanding any such consent, each Party shall remain at all times fully liable for its respective responsibilities under the Collaboration. In the event that utilization of the services of a Third Party necessitates the disclosure of Confidential Information, then the disclosing Party shall cause such Third Party to enter into a confidentiality agreement with the disclosing Party at least as restrictive as the confidentiality obligations binding the disclosing Party hereunder.
Sample 1
Conduct of Collaboration 
Sample 1Sample 2Sample 3See All (20)
AutoNDA by SimpleDocs

Related to Conduct of Collaboration

  • Conduct of Research Program Each Party:

  • Conduct of Research The Parties shall use Diligent Efforts to conduct their respective tasks, as assigned under the Research Plan, throughout the Mode of Action Program and shall conduct the Mode of Action Program in good scientific manner, and in compliance in all material respects with the requirements of applicable laws, rules and regulations and all applicable good laboratory practices to attempt to achieve their objectives efficiently and expeditiously.

  • Conduct of Third Party Claims 11.4.1 If the matter or circumstance that may give rise to a claim against a Seller under this Agreement or any relevant Local Transfer Document for breach of any Seller’s Warranty (other than a Tax Warranty) is a result of or in connection with a claim by a third party (a “Third Party Claim”) then:

  • Conduct of the Business Each of the Company and Parent covenants and agrees that:

  • Prosecution and Maintenance of Patent Rights (a) Ardelyx shall be responsible for the preparation, filing, prosecution (including without limitation conducting any interferences, oppositions, reissue proceedings and reexaminations) and maintenance of the Listed Patents, unless and until Sanofi has exercised the Option to Continue and Ardelyx has received the Continuation Milestone. Ardelyx agrees to prosecute and maintain the Listed Patents in those countries set forth on Exhibit C. A detail of Patent Costs incurred by Ardelyx in prosecuting and maintaining the Listed Patents prior to the Effective Date is set forth on Exhibit B; provided, however, that the costs and expenses set forth on Exhibit B do not include those costs and expenses incurred by Ardelyx in the drafting and filing of the Listed Patents. Ardelyx will bear the [***] of Patent Costs after the Effective Date and prior to Sanofi’s exercise of the Option to Continue. After Ardelyx has paid such amount, Sanofi shall reimburse Ardelyx for any additional Patent Costs incurred by Ardelyx after the Effective Date during the Term until such time as Sanofi exercises the Option to Continue and Ardelyx has received the Continuation Milestone. Ardelyx shall submit invoices to Sanofi at the beginning of each Calendar Quarter, which invoice shall detail the Patent Costs in the previous Calendar Quarter and, if applicable, include all copies of invoices from outside counsel. Sanofi shall pay each invoice within thirty (30) days of its receipt thereof. During the time that Ardelyx is responsible for the prosecution of the Listed Patents, Ardelyx shall provide Sanofi with advance copies of, and a reasonable opportunity to comment upon, proposed patent filings, related prosecution strategies and proposed correspondence with patent officials or other Third Parties relating to any Listed Patents. Ardelyx, in the course of such activities, will consider comments received from Sanofi with respect to such proposed filings, strategies and correspondence in good faith and will not unreasonably reject such comments to the extent such comments could reasonably be deemed to impact Ardelyx Compounds. In any event, Ardelyx will not finally abandon any claims and will not limit any claims that are specific to Ardelyx Compounds without Sanofi’s prior written consent. Ardelyx shall cooperate to assist Sanofi in assuming the prosecution and maintenance of the Listed Patents as provided by Section 8.4(i), including by transferring to Sanofi the patent files associated with such Licensed Products and providing any other information reasonably requested by Sanofi and access to the relevant inventors.

  • Filing Prosecution and Maintenance of Patent Rights 7.1 Patent Filing, Prosecution and Maintenance.

  • Prosecution and Maintenance of Patents Licensee shall prosecute and maintain in the Territory, through outside counsel, the patents and patent applications that are set forth in Schedule C. Following the [***] milestone referred to in Section 7.02, however, [***]. Each party shall bear its own costs related to such prosecution and maintenance and shall manage any administrative challenge to [***], including any interference, post-grant review, inter partes review, derivation proceeding, opposition, reexamination, reissue or similar administrative proceeding. Licensee shall manage any such interference, post-grant review, inter partes review, derivation proceeding, opposition, reexamination, reissue or similar administrative proceeding through outside counsel. [***]. Licensee shall keep Merck advised of such prosecution and maintenance of patents and applications set forth in Schedule C and upon the written request of Merck, will provide advance copies of any substantive papers to be filed in connection with such prosecution and maintenance, including such applications, amendments thereto and other related correspondence to and from patent offices.

  • Conduct of the Company’s Business The Company covenants and agrees that, prior to the Effective Time, unless Parent shall otherwise consent in writing or as otherwise expressly contemplated by this Agreement:

  • Prosecution and Maintenance Each party retains the sole right to protect at its sole discretion the Intellectual Property and Technology owned by such party, including, without limitation, deciding whether to file and prosecute applications to register patents, copyrights and mask work rights included in such Intellectual Property, whether to abandon prosecution of such applications, and whether to discontinue payment of any maintenance or renewal fees with respect to any patents included in such Intellectual Property.

  • Conduct of Claims 31.6.1 The Indemnifying Party may at its own expense and with the assistance and co-operation of the Indemnified Party have the conduct of the Third Party Claim including its settlement and the Indemnified Party will not, unless the Indemnifying Party has failed to resolve the Third Party Claim within a reasonable period (and the Indemnified Party has notified the Indemnifying Party in writing that it is of the opinion that such reasonable period has expired), take any action to settle or pursue the Third Party Claim

Time is Money Join Law Insider Premium to draft better contracts faster.